2001: A year of major advances in anthrax toxin research

Trends in Microbiology

Volumn 10, Issue 6, 2002, Pages 287-293

  Mourez, Michael ^a   Lacy, D Borden ^a   Cunningham, Kristina ^a   Legmann, Rachel ^a   Sellman, Bret R ^a,b   Mogridge, Jeremy ^a,c   Collier, R John ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX TOXIN; RECEPTOR; TOXIN ANTIBODY; TOXIN RECEPTOR; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

AMINO ACID SEQUENCE; ANTHRAX; BACILLUS ANTHRACIS; BACTERIAL SPORE; BIOLOGICAL WARFARE; CANCER; CRYSTAL STRUCTURE; DEATH; EDEMA; HERBIVORY; HUMAN; INFECTION PREVENTION; MEDICAL RESEARCH; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ASSEMBLY; PROTEIN DOMAIN; REVIEW; SPECIES DIFFERENCE; SPORE GERMINATION; TOXIN STRUCTURE;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; CARRIER PROTEINS; GUINEA PIGS; MALE; MODELS, IMMUNOLOGICAL; MODELS, MOLECULAR; RATS; RESEARCH; VIPER VENOMS;

ANTHRAX; BACILLUS ANTHRACIS; BACTERIA (MICROORGANISMS); BOS TAURUS; POSIBACTERIA;

EID: 0036603521     PISSN: 0966842X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-842X(02)02369-7     Document Type: Review

References (35)

1. Anthrax
2. Toxins of Bacillus anthracis
3. Molecular pathogenesis of Bacillus anthracis infection
4. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor
5. Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor
6. Kif1C, a kinesin-like motor protein, mediates mouse macrophage resistance to anthrax lethal factor
7. On the role of macrophages in anthrax
8. Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFNγ-induced release of NO and TNFα
9. Macrophage-derived cell lines do not express proinflammatory cytokines after exposure to Bacillus anthracis lethal toxin
10. Fate of germinated Bacillus anthracis spores in primary murine macrophages
11. Early Bacillus anthracis-macrophage interactions: Intracellular survival and escape
12. Anthrax
13. Anthrax as a biological weapon: Medical and public health management. Working Group on Civilian Biodefense
14. Bioterrorism-related inhalational anthrax: The first 10 cases reported in the United States
15. Quickening the pace of anthrax research: Three advances point towards possible therapies
16. Anthrax protective antigen interacts with a specific receptor on the surface of CHO-K1 cells
17. Identification of the cellular receptor for anthrax toxin
18. Anthrax toxin entry into polarized epithelial cells
19. Crystal structure of the anthrax toxin protective antigen
20. Structural basis for the activation of anthrax adenylyl cyclase exotoxin by calmodulin
21. Crystal structure of the anthrax lethal factor
22. Involvement of domain 3 in oligomerization by the protective antigen moiety of anthrax toxin
23. Mapping the lethal factor and edema factor binding sites on oligomeric anthrax protective antigen
24. The lethal and edema factors of anthrax toxin bind only to oligomeric forms of the protective antigen
25. Mapping the anthrax protective antigen binding site on the lethal and edema factors
26. Stoichiometry of anthrax toxin complexes
27. Oligomerization of anthrax toxin protective antigen and binding of lethal factor during endocytic uptake into mammalian cells
28. Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs
29. Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization
30. Designing a polyvalent inhibitor of anthrax toxin
31. Dominant-negative mutants of a toxin subunit: An approach to therapy of anthrax
32. Point mutations in anthrax protective antigen that block translocation
33. Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways
34. Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin
35. Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin